Optimal Use Guidelines Issued for Opdivo, Keytruda for Melanoma, NSCLC Use

The Ministry of Health, Labor and Welfare (MHLW) on February 14 issued “optimal use promotion guidelines” for the anti-PD-1 antibodies Opdivo (nivolumab) and Keytruda (pembrolizumab) for the treatment of melanoma and non-small cell lung cancer (NSCLC). The guidelines, which were...read more